@article{bibcite_459,
  keywords = {Computer Simulation, Animals, Drug Design, Humans, Quinoxalines, Structure-Activity Relationship, Protein Kinase Inhibitors, Isoquinolines, Neoplasms, Receptor, EphB2, Xanthine},
  author = {A. Unzue and K. Lafleur and H. Zhao and T. Zhou and J. Dong and P. Kolb and J. Liebl and S. Zahler and A. Caflisch and C. Nevado},
  title = {Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation},
  abstract = {<p>Several selective and potent EphB4 inhibitors have been discovered, optimized and biophysically characterized by our groups over the past years. On the outset of these discoveries high throughput docking techniques were applied. Herein, we review the optimization campaigns started from three of these hits (Xan-A1, Pyr-A1 and Qui-A1) with emphasis on their in depth <i>in vitro</i> and <i>in vivo</i> characterization, together with previously unpublished angiogenesis and fluorescence based assays.</p>},
  year = {2016},
  journal = {European Journal of Medicinal Chemistry},
  volume = {112},
  chapter = {347},
  pages = {347-366},
  month = {2016 Apr 13},
  issn = {1768-3254},
  doi = {10.1016/j.ejmech.2016.01.057},
  language = {eng},
}